{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:55:50Z","timestamp":1762005350683,"version":"3.44.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K23HL151672-01"],"award-info":[{"award-number":["1K23HL151672-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["813396","COVID-19"],"award-info":[{"award-number":["813396","COVID-19"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ahj.2021.06.004","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T06:24:33Z","timestamp":1623479073000},"page":"46-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Renin\u2013angiotensin\u2013aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system"],"prefix":"10.1016","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-1143","authenticated-orcid":false,"given":"Alexander T","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoutzu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Y","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary K.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.06.004_bib0001","first-page":"m8102","article-title":"Rapid response: RE: Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19","volume":"368","author":"Sommerstein","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2021.06.004_bib0002","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.004_bib0003","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpu086","article-title":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","volume":"28","author":"Furuhashi","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2021.06.004_bib0004","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ahj.2021.06.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00217.2020","article-title":"COVID-19, ACE2, and the cardiovascular consequences","volume":"318","author":"South","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0006","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2021.06.004_bib0007","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.06.004_bib0008","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jama.2020.11301","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality","volume":"324","author":"Fosb\u00f8l","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.06.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/heartjnl-2020-317393","article-title":"Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people","author":"Hippisley-Cox","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2021.06.004_bib0010","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.06.004_bib0011","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.ahj.2021.06.004_bib0012","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-Angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.06.004_bib0013","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0014","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/cid\/ciaa624","article-title":"Association of Renin-angiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19)- related outcomes in korea: a nationwide population-based cohort study","volume":"71","author":"Jung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ahj.2021.06.004_bib0015","doi-asserted-by":"crossref","first-page":"taaa069","DOI":"10.1093\/jtm\/taaa069","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection","volume":"27","author":"Chodick","year":"2020","journal-title":"J Travel Med"},{"key":"10.1016\/j.ahj.2021.06.004_bib0016","first-page":"hpaa168","article-title":"Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study","author":"Dublin","year":"2020","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2021.06.004_bib0017","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40264-020-00994-5","article-title":"ITA-COVID-19: RAAS inhibitor group. renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with covid-19: a retrospective Italian cohort study of 43,000 patients","volume":"43","author":"Trifir\u00f2","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.ahj.2021.06.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018086","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19","author":"Khera","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2021.06.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019669","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use and covid-19 infection among 824 650 patients with hypertension from a us integrated healthcare system","volume":"10","author":"An","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2021.06.004_bib0020","article-title":"Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States Veterans Aged 54-75 Years","author":"Rentsch","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1016\/j.ahj.2021.06.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248080","article-title":"Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans","volume":"16","author":"Derington","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2021.06.004_bib0022","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2021.06.004_bib0023","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0024","doi-asserted-by":"crossref","first-page":"H1351","DOI":"10.1152\/ajpheart.01186.2004","article-title":"Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure","volume":"289","author":"Karram","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0025","first-page":"1","article-title":"Prescription drug use among adults aged 40-79 in the United States and Canada","author":"Hales","year":"2019","journal-title":"NCHS Data Brief"},{"unstructured":"Department of Veterans Affairs, Office of Research and Development. COVID-19 Shared Data Resource. Available at: https:\/\/vhacdwdwhweb100.vha.med.va.gov\/phenotype\/index.php\/COVID-19:Shared_Data_Resource. Accessed. Accessed November 3, 2020.","key":"10.1016\/j.ahj.2021.06.004_bib0026"},{"key":"10.1016\/j.ahj.2021.06.004_bib0027","doi-asserted-by":"crossref","first-page":"680","DOI":"10.15585\/mmwr.mm6922e1","volume":"69","author":"Jorden","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ahj.2021.06.004_bib0028","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0029","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.06.004_bib0030","article-title":"National trends in the ambulatory treatment of hypertension in the United States, 1997-2012","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2021.06.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009992","article-title":"Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"7","author":"Ku","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2021.06.004_bib0032","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF Registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0033","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0034","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2021.06.004_bib0035","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ahj.2021.06.004_bib0036","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2021.06.004_bib0037","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cardfail.2019.01.019","article-title":"Accuracy of administrative coding to identify reduced and preserved left ventricular ejection fraction","volume":"25","author":"Heidenreich","year":"2019","journal-title":"J Card Fail"},{"unstructured":"US Census Bureau. American Community Survey. 2018; https:\/\/www.census.gov\/programs-surveys\/acs\/about.html. Accessed February 9, 2019.","key":"10.1016\/j.ahj.2021.06.004_bib0038"},{"year":"2008","author":"Bonito","series-title":"Creation of New Race-Ethnicity Codes and Socioeconomic Status (SES) Indicators for Medicare Beneficiaries: Final Report","key":"10.1016\/j.ahj.2021.06.004_bib0039"},{"key":"10.1016\/j.ahj.2021.06.004_bib0040","doi-asserted-by":"crossref","first-page":"706","DOI":"10.7326\/M17-0767","article-title":"Concentration of potentially preventable spending among high-cost medicare subpopulations: an observational study","volume":"167","author":"Figueroa","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2021.06.004_bib0041","first-page":"e3398","article-title":"Haemoglobin A1c is a predictor of COVID-19 severity in patients with diabetes","author":"Merzon","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ahj.2021.06.004_bib0042","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jmv.26444","article-title":"Anemia is associated with severe illness in COVID-19: A retrospective cohort study","volume":"93","author":"Tao","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0043","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016502","article-title":"Association of diagnostic coding-based frailty and outcomes in patients with heart failure: a report from the veterans affairs health system","volume":"9","author":"Kohsaka","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2021.06.004_bib0044","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: Issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2021.06.004_bib0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12874-020-01068-x","article-title":"Multiple imputation with missing indicators as proxies for unmeasured variables: simulation study","volume":"20","author":"Sperrin","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0046","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1020371312283","article-title":"Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization","volume":"2","author":"Hirano","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0047","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.ahj.2021.06.004_bib0048","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/10543406.2020.1730868","article-title":"Comparison of propensity score methods for pre-specified subgroup analysis with survival data","volume":"30","author":"Izem","year":"2020","journal-title":"J Biopharm Stat"},{"year":"2010","author":"West","series-title":"Comparative Effectiveness Review Methods: Clinical Heterogeneity [Internet]","key":"10.1016\/j.ahj.2021.06.004_bib0049"},{"doi-asserted-by":"crossref","unstructured":"Semenzato L, Botton J, Drouin J, et\u00a0al. Antihypertensive Drugs and COVID-19 Risk: A cohort study of 2 million hypertensive patients. hypertension. 2021;77:833-842. doi:10.1161\/HYPERTENSIONAHA.120.16314.","key":"10.1016\/j.ahj.2021.06.004_bib0050","DOI":"10.1161\/HYPERTENSIONAHA.120.16314"},{"key":"10.1016\/j.ahj.2021.06.004_bib0051","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the e-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"year":"2020","author":"American College of Cardiology","series-title":"HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19","key":"10.1016\/j.ahj.2021.06.004_bib0052"},{"key":"10.1016\/j.ahj.2021.06.004_bib0053","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/M20-1515","article-title":"Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review","volume":"173","author":"Mackey","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2021.06.004_bib0054","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chest.2020.04.010","article-title":"Medical treatment expert group for covid-19. risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China","volume":"158","author":"Chen","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2021.06.004_bib0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic","volume":"16","author":"South","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ahj.2021.06.004_bib0056","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on days alive and out of the hospital in patients admitted with covid-19: a randomized clinical trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.06.004_bib0057","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ahj.2021.06.004_bib0058","first-page":"57","article-title":"Osteoporotic Fractures in Men (MrOS) Research Group. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men","volume":"46","author":"Kwok","year":"2017","journal-title":"Age Ageing"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321001514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321001514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:06:59Z","timestamp":1757570819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321001514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":58,"alternative-id":["S0002870321001514"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.06.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin\u2013angiotensin\u2013aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}